Reaxys® Significantly Expands its Content and Interface to Deliver Chemistry Information to Researchers Across Disciplines
AMSTERDAM, April 8, 2013 /PRNewswire/ –
Elsevier [http://www.elsevier.com ], a world-leading provider of scientific, technical
and medical information products and services, today announced a significant content
expansion and an improved and enriched user interface for Reaxys
[http://www.elsevier.com/reaxys ], a unique chemistry workflow solution. With this
interface and content update Reaxys now supports the entire chemistry workflow resulting
in a faster and more efficient research process. Reaxys now encompasses over 16,000
periodicals and has coverage of over 30 million reactions and over 500 million
experimentally measured data.
Designed by chemists for chemists, Reaxys enables researchers to advance quickly and
confidently through their workflow in order to deliver superior outcomes. An independent
survey of 200 users of the product found that the research process was conducted on
average 30 percent quicker with Reaxys, when compared to existing alternatives; and
related R&D costs were estimated to be reduced by almost 25 percent.
“The pressure on chemists to deliver results is considerable whether they’re working
in the public or private sector. Like in many other fields, the quantity of data is
increasing exponentially. Researchers do not have time to read everything, so they need a
solution that helps them to quickly find the right information sources. 95 percent of the
top global spenders in pharma use Reaxys because it is flexible enough to accommodate, for
example, all the content that researchers need, displayed in one common user interface,
ensuring that they don’t have to switch from one system to another,” said Dr. Juergen
Swienty-Busch, Director of Product Management for Reaxys. “The two most critical things
for our customers are innovation and efficiency. By embedding the information they need
into their workflow, whether in their E-lab notebook to record experiments or by using an
API to display results in a different environment, Reaxys enables researchers to work more
efficiently and progress towards their innovation objectives.”
“Reaxys’ new content and capability expansion of the user interface expands horizons
for researchers across all chemistry related domains. Reaxys, in combination with Reaxys
Medicinal Chemistry, the domain specific solution, enables users to make more confident
decisions about compound selection and synthesis much earlier in the process, improving
the likelihood of developing a successful drug and reducing the costs associated with a
drug candidate failure in the pre-clinical or clinical development stages,” said Meeuwis
van Arkel, Vice President Product Development at Elsevier. “Reaxys is interoperable with
other innovative solutions which assist researchers across disciplines; this
interoperability is vital in promoting organizational efficiency and R&D efficacy.”
Reaxys is a key pillar of Elsevier Life Science Solutions, a suite of interoperable,
domain-specific, decision support tools which span the discovery and development workflow.
Reaxys works with solutions including; ScienceDirect, for immediate full-text access;
Scopus, for in-depth bibliometric information; PharmaPendium for a comprehensive view into
FDA/EMA approved drugs.
To view Reaxys’ new interface and for more information go to:
Reaxys(R) is a workflow solution for research chemists. Offering a wealth of
experimentally validated information, Reaxys(R) combines reaction and substance data in
organic, organometallic, inorganic and physical chemistry with synthesis planning.
Researchers can get the information they need in a single overview, from source
publications carefully selected for their importance and relevance to research chemists.
Elsevier continues to engage with the chemistry community to ensure that Reaxys(R)
continues to reflect how chemists think and work. For more information please visit Reaxys
Reaxys and the Reaxys trademark are owned and protected by Reed Elsevier Properties SA
and used under license.
Elsevier is a world-leading provider of scientific, technical and medical information
products and services. The company works in partnership with the global science and health
communities to publish more than 2,000 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier’s online
solutions include ScienceDirect [http://www.sciencedirect.com ], Scopus
[http://www.scopus.com ], Reaxys [http://www.reaxys.com ], ClinicalKey
[https://www.clinicalkey.com ] and Mosby’s Suite [http://www.confidenceconnected.com ],
which enhance the productivity of science and health professionals, and the SciVal suite
[http://www.scival.com ] and MEDai’s Pinpoint Review [http://www.medai.com ], which help
research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier [http://www.elsevier.com ]
employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC
[http://www.reedelsevier.com ], a world leading provider of professional information
solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly
owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext
Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media contact Liz Griffioen Elsevier +31-20-485-2247 firstname.lastname@example.org